| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of Mps1-IN-3 is monopolar spindle 1 (Mps1) kinase, also known as TTK protein kinase. It is a potent and selective MPS1 inhibitor with an IC₅₀ of 50 nM. By inhibiting Mps1 activity, it disrupts chromosome alignment and checkpoint signaling, leading to chromosomal missegregation, aneuploidy, and apoptosis in rapidly dividing cells.
|
|---|---|
| ln Vitro |
Mps1-IN-3, having an IC50 of 50 nM, is a strong inhibitor of MPS1 kinase. Mps1-IN-3 has an IC50 of about 5 µM, which prevents U251 glioblastoma cells from proliferating. Mps1-IN-3 (2 μM) abrogates the checkpoint altogether [1].
In vitro, Mps1-IN-3 potently inhibits MPS1 kinase activity with an IC₅₀ of 50 nM. It inhibits the proliferation of U251 glioblastoma cells with an IC₅₀ of approximately 5 µM. MPS1 inhibition efficiently sensitizes glioblastoma cells to antimitotic agents. |
| ln Vivo |
In animal tumor models, Mps1-IN-3 (2 mg/kg, intravenously) sensitizes glioblastoma cells without causing harm and extending their survival [1].
In vivo, Mps1-IN-3 (2 mg/kg, i.v.) enhances the sensitivity of glioblastoma cells in murine tumor models, extends survival, and exhibits no toxicity. The compound has phenotypic consequences similar to those reported for other published MPS1 inhibitors. |
| Enzyme Assay |
For in vitro kinase assays, Mps1-IN-3 is tested against MPS1 and other kinases. Standard protocols involve incubating the kinase with a substrate and ATP in the presence of varying concentrations of Mps1-IN-3 (0.1-1000 nM). Activity is measured by radioactive or fluorescence-based detection. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for Mps1-IN-3 involve treating cancer cell lines (e.g., U251 glioblastoma) with the compound at concentrations of 0.01-10 µM for 24-72 hours. Cell proliferation is measured by MTT or CellTiter-Glo assays. Effects on mitotic progression and checkpoint signaling are assessed by immunofluorescence and Western blotting.
|
| Animal Protocol |
In vivo studies with Mps1-IN-3 are conducted in murine tumor models. Typical protocols involve administering the compound intravenously at 2 mg/kg. Efficacy is assessed by tumor growth inhibition and survival analysis. The compound enhances sensitivity to antimitotic agents.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mps1-IN-3 have been characterized in preclinical studies. The compound is administered intravenously. It distributes to tumor tissue. Detailed PK parameters including half-life and exposure are available from research publications.
|
| Toxicity/Toxicokinetics |
Toxicology data for Mps1-IN-3 indicate that it exhibits no toxicity at the therapeutic dose of 2 mg/kg (i.v.) in murine models. The compound is well-tolerated. Comprehensive toxicology data are available from research publications.
|
| References | |
| Additional Infomation |
Mps1-IN-3 is a potent and selective MPS1 kinase inhibitor used in cancer research. It disrupts mitotic checkpoint signaling and induces apoptosis in cancer cells. It is used to study mitotic control and spindle assembly checkpoint function. No clinical trials or FDA approvals exist.
|
| Molecular Formula |
C26H31N7O4S
|
|---|---|
| Molecular Weight |
537.64
|
| Exact Mass |
537.215
|
| CAS # |
1609584-72-6
|
| Related CAS # |
Mps1-IN-3 hydrochloride
|
| PubChem CID |
91885443
|
| Appearance |
Solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.677
|
| LogP |
0.57
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
866
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC3=C2NC=N3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC
|
| InChi Key |
OFRMASLPWOMYHN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H31N7O4S/c1-16(2)38(35,36)22-7-5-4-6-20(22)29-25-23-24(28-15-27-23)31-26(32-25)30-19-9-8-17(14-21(19)37-3)33-12-10-18(34)11-13-33/h4-9,14-16,18,34H,10-13H2,1-3H3,(H3,27,28,29,30,31,32)
|
| Chemical Name |
1-[3-methoxy-4-[[6-(2-propan-2-ylsulfonylanilino)-7H-purin-2-yl]amino]phenyl]piperidin-4-ol
|
| Synonyms |
Mps1-IN3 Mps1 IN3 Mps1-IN-3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~31.25 mg/mL (~58.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.65 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8600 mL | 9.2999 mL | 18.5998 mL | |
| 5 mM | 0.3720 mL | 1.8600 mL | 3.7200 mL | |
| 10 mM | 0.1860 mL | 0.9300 mL | 1.8600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
